期刊文献+

雄激素受体在乳腺癌不同分子分型中的表达差异 被引量:9

下载PDF
导出
摘要 目的探讨雄激素受体(AR)在不同乳腺癌分子分型中表达的差异。方法收集浸润性乳腺癌239例,免疫组化方法检测ER、PR、HER-2和AR的表达;对于HER-2(++)的病例,进一步应用FISH法检测HER-2基因的扩增。根据免疫组化及FISH法检测结果将乳腺癌分为4型,分析AR在不同乳腺癌分子分型中的表达。结果 AR的阳性率为89.1%;AR在Luminal A型、Luminal B型及HER-2过表达型乳腺癌中的阳性率分别为97.2%,100.0%和100.0%,而在Basal-like型乳腺癌中阳性率为26.9%,差异具有统计学意义(P<0.01)。结论 AR在Luminal A、Luminal B和HER-2过表达型乳腺癌中具有很高的阳性率,而在Basal-like型乳腺癌中表达率则很低。
出处 《浙江实用医学》 2016年第2期94-97,共4页 Zhejiang Practical Medicine
  • 相关文献

参考文献14

  • 1Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol, 2011, 22(8): 1736.
  • 2Hall RE, Aspinall JO, Horsfall D J, et al. Expression of the androgen receptor and an androgen-reponsive protein, apolipoprotein D, in human breast cancer . Br J Cancer, 1996, 74(8): 1175.
  • 3乳腺癌HER2检测指南(2014版)[J].中华病理学杂志,2014,43(4):262-267. 被引量:295
  • 4Kim MJ, Ro JY, Ahn $11, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and HER -2/neu overexpressing phenotype. Hum Pathol, 2006, 37(9): 1217.
  • 5Carey LA, Perou CM, Livasy CA, et al. Race, Breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA, 2006, 295(21): 2492.
  • 6袁中玉,王树森,朱美琴,郑磊,罗文标,周中梅,管忠震.不同分子亚型乳腺癌的临床特征和预后[J].中华肿瘤杂志,2008,30(6):456-461. 被引量:55
  • 7Ando S, De Amicis F, Rago V, et al. Breast cancer: from estrogen to androgen receptor . Mol CellEndocer, 2002, 193:121.
  • 8吴晶晶,陈曦.乳腺癌相关雄激素受体的研究进展[J].临床肿瘤学杂志,2014,19(3):280-283. 被引量:7
  • 9Yu Q,Niu N, Liu N, et al. Expression of androgen receptor in breast cancer and its significance as a prognostic factor . Ann Oncol, 2011, 22:1288.
  • 10Agoff SN, Swanson PE, Linden H, et al. Androgen receptor expression in estrogen receptor -negative breast cancer. Immunohistochemical, clinical, and prognostic association. Am J Clin Pathol, 2003, 120(5): 725.

二级参考文献73

  • 1张瑰红,施达仁,梁晓曼,侯景辉,康苏娅,朱卫东,李晓兵,邵云,陈丽荣,周燕.显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J].中华病理学杂志,2006,35(10):580-583. 被引量:29
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature, 2002, 415:530-536.
  • 4Sotiriou C, Neo SY, MeShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population based study. Proc Natl Acad Sci U S A, 2003, 100: 10393- 10398.
  • 5Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer, 2007, 109:25-32.
  • 6Jones C, Nonni AV, Fulford L, et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer, 2001, 85:422-427.
  • 7Cunningham JE, Butler WM. Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis. Breast Cancer Res Treat, 2004, 88 : 161-176.
  • 8Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006, 295:2492-2502.
  • 9Lohrisch C, Piccart M. An overview of HER2. Semin Oncol, 2001, 28(6 Suppl 18) :3-11.
  • 10Vicini FA, Recht A. Age at diagnosis and outcome for women with ductal carcinoma-in-situ of the breast: a critical review of the literature. J Clin Oncol, 2002, 20:2736-2744.

共引文献368

同被引文献39

引证文献9

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部